William Joseph Chapin, MD, MSCE
Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
10 South Pavilion
3400 Civic Center Blvd
Philadelphia, PA 19104
10 South Pavilion
3400 Civic Center Blvd
Philadelphia, PA 19104
Education:
BS (Molecular Biology, Spanish, Honors in the Liberal Arts)
University of Wisconsin-Madison , 2012.
MD (Medicine )
The University of Chicago Pritzeker School of Medicine , 2016.
MSCE (Clinical Epidemiology)
University of Pennsylvania Perelman School of Medicine , 2022.
Permanent linkBS (Molecular Biology, Spanish, Honors in the Liberal Arts)
University of Wisconsin-Madison , 2012.
MD (Medicine )
The University of Chicago Pritzeker School of Medicine , 2016.
MSCE (Clinical Epidemiology)
University of Pennsylvania Perelman School of Medicine , 2022.
Selected Publications
Nishwant Swami , Wei-Ting Hwang , Ronac Mamtani , Mark O'Hara , William Chapin: Real-world survival comparison of second-line treatment strategies for patients with RAS/RAF wild-type, right-sided metastatic colorectal cancer. Journal of Clinical Oncology 43(4_suppl): 73, Jan 2025.Margalit O, Stemmer A, Chapin WJ, Schacham-Shmueli E, Kopetz S, Andre T, Overman MJ, Pietrantonio F, Boursi B: Duration of Immunotherapy in dMMR/MSI-H Metastatic Colorectal Cancer Patients. European Journal of Cancer 212: 114336, Nov 2024 Notes: doi: 10.1016/j.ejca.2024.114336.
Chapin WJ, Hwang W, Mamtani R, O’Hara MH: Real-world uptake and effectiveness of triplet versus doublet chemotherapy with bevacizumab in patients with metastatic colorectal cancer in the United States. ESMO Gastrointestinal Oncology 5: 100087, Sep 2024.
Chapin WJ, Hwang W, Mamtani R, O’Hara MH: Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer. JAMA Netw Open 7(7): e2424855, July 2024.
Rathore S, Reiss KA, Teitelbaum UR, Chapin WJ: Exploring the association of smoking status with clinical outcomes in patients with mPDAC treated on a clinical trial of maintenance niraparib plus immune checkpoint blockade. American Society of Clinical Oncology Annual Meeting, Chicago, IL. 42(suppl 16): Abstract e16302, May 2024 Notes: "Poster Presentation"
William Joseph Chapin, Wei-Ting Hwang, Ronac Mamtani, and Mark H. O'Hara: Real-world comparison of low- versus high-dose continuous 5FU infusion in patients receiving triplet chemotherapy plus bevacizumab for newly diagnosed metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 42(3_suppl): 62-62, Jan 2024.
William Joseph Chapin, Wei-Ting Hwang, Ronac Mamtani, Mark H O'Hara: Real-world comparison of triplet-versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC). The American Society of Clinical Oncology Annual meeting, Chicago, IL. American Society of Clinical Oncology, 41(16_suppl): 3574-3574, Jun 2023 Notes: "Oral Presentation"
William Joseph Chapin, Parul Agarwal, Lisa DiCicco, Rayleigh Palmer, Nadia Cenou, Alexander Chan Chi Huang, Thomas Benjamin Karasic: Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers. American Society of Clinical Oncology Annual Meeting, Chicago, IL. 41(16_suppl): TPS4184-TPS4184, June 2023 Notes: "Oral Presentation"
Alese OB, Wu C, Chapin WJ, Ulanja MB, Zheng-Lin B, Amankwah M, Eads J.: Update on Emerging Therapies for Advanced Colorectal Cancer. Am Soc Clin Oncol Educ Book 43: e389574. May 2023.
Chapin WJ, Hwang WT, Karasic TB, McCarthy AM, Kaplan DE. : Comparison of Nivolumab and Sorafenib for First Systemic Therapy in Patients with Hepatocellular Carcinoma and Child-Pugh B Cirrhosis. Cancer Medicine 12(1): 189-199. Jan 2023.